论文部分内容阅读
目的:探讨原发性免疫性血小板减少症(PITP)采用大剂量地塞米松治疗后的临床疗效。方法:选取2013年1月至2015年6月本院收治的原发性免疫性血小板减少症患者70例,采用随机平均数字分配法将70例患者分为A组(35例)、B组(35例),A组使用大剂量地塞米松40 mg/d,静脉滴注连续冲击治疗4 d为1个疗程;B组使用泼尼松1 mg·kg-1·d-1,给药途径为口服,连续用药4周为1个疗程。对比A、B两组患者的血小板数变化情况。结果:治疗第5天后,A组的显效率、总有效率均高于B组,组间比较,差异具有统计学意义(P<0.05)。治疗4 d、7 d期间,A组患者不良反应发生率为2.9%。B组患者不良反应发生率为14.3%,组间比较,差异具有统计学意义(P<0.05)。结论:采用大剂量地塞米松治疗PITP起效快、安全性好、不良发应发生率小,适合短期冲击治疗。
Objective: To investigate the clinical efficacy of high-dose dexamethasone in patients with idiopathic thrombocytopenia (PITP). Methods: Seventy patients with primary immune thrombocytopenia who were admitted to our hospital from January 2013 to June 2015 were enrolled. A total of 70 patients were divided into group A (n = 35), group B (n = 35 cases in group A), high-dose dexamethasone 40 mg / d in group A and continuous treatment with intravenous drip for 4 days for one course of treatment. Group B received prednisone 1 mg · kg -1 · d -1, For oral administration, continuous treatment for 4 weeks for a course of treatment. Comparison of A, B two groups of patients with changes in platelet count. Results: After 5 days of treatment, the markedly effective rate and total effective rate of group A were higher than that of group B, and the difference was statistically significant (P <0.05). During the fourth and seventh days of treatment, the incidence of adverse reactions in group A was 2.9%. The incidence of adverse reactions in group B was 14.3%. There was significant difference between groups (P <0.05). Conclusion: The high-dose dexamethasone treatment of PITP fast onset, good safety, the incidence of adverse reactions is small, suitable for short-term impact treatment.